Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab

Annals of Hematology

Volumn 79, Issue 3, 2000, Pages 161-164

  Stiegler, H ^a   Fischer, Y ^a   Steiner, S ^b   Strauer, B E ^b   Reinauer, H ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Automated cell counter; c7E3 Fab; EDTA; Pseudothrombocytopenia

Indexed keywords

ABCIXIMAB; EDETIC ACID; FIBRINOGEN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; EMERGENCY SURGERY; FEMALE; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; EDETIC ACID; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0034043744     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050573     Document Type: Article

References (13)

1. The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330:956-961
2. The EPILOG Investigators (1997) Platelet glycoprotein IIb/ IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
3. The EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 352:87-92
4. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM (1998) Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 32:311-319
5. Stiegler H, Fischer Y, Steiner S (1999) Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists. Lancet 353:1185
6. Stiegler H, Fischer Y, Niederau C, Steiner S, Hermsen D, Reinauer H (1999) Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/ IIIa antagonist c7E3 Fab. Ann Hematol 78 [Suppl I]: A17
7. Campeau L (1976) Grading of angina pectoris. Circulation 54:522-523
8. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142-154
9. Coller BS (1997) GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 78:730-735
10. Christopoulos CG, Machin SJ (1994) A new type of pseudothrombocytopenia: EDTA-mediated aggregation of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 87:650-652
11. Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne AE (1982) Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetra-acetate. Blood 59:157-161
12. Gschwandtner ME, Siostrzonek P, Bodinger C, Neunteufl T, Zauner C, Heinz G, Maurer G, Panzer S (1997) Documented sudden onset of pseudothrombocytopenia. Ann Hematol 74:283-285
13. Bartels PC, Schoorl M, Lombarts AJ (1997) Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest 57:629-636